Lung Cancer News
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.
Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.
Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.
The US Food and Drug Administration approved osimertinib for the treatment of EGFR T790M mutation-positive NSCLC.
In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.
Racial disparities in treatment and outcomes persist among patients diagnosed with NSCLC in spite of advances in curative therapies.
SBRT may be an effective strategy for elderly patients with unresectable lung cancer.
Definitive reirradiation of thoracic cancers with IMPT can provide durable local control with minimal toxicity and can extend survival.
Post-radiotherapy samples in 20 of 22 recurrences revealed that 15 of these patients (75%) had an increase in CTC counts.
In an analysis of metastatic lung cancer treated with thoracic radiotherapy and immunotherapy, 3 patients had severe toxicity.
Resistance to EGFR-targeted therapies may not be permanent; a single biopsy is insufficient for fully understanding the nature of therapy resistance.
Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.
Currently-available multikinase inhibitors that target RET kinase had limited activity in patients with non-small cell lung cancer (NSCLC) with RET rearrangements.
Dako/Agilent 28-8, Dako/Agilent 22c3, and Leica Bond E1L3N yield similar results for PD-L1 expression testing in tumor cells, though Ventana SP142 is a less effective assay.
The addition of pravastatin to the first-line standard of care failed to provide benefit for patients with small-cell lung cancer (SCLC).
Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).
No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
Only 262,700 of the eligible 6.8 million smokers or ex-smokers underwent LDCT in 2015.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Bladder-sparing Therapy Outcomes Similar to Cystectomy in Bladder Cancer
- Prostate Cancer Risk and Fruit Intake
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer
- Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer
- Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results
- Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer
- Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD
- Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL